alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Commercialization Accelerator 

Program (CAP)

CAP BROADENS S&T’S IMPACT ACROSS 

THE HOMELAND SECURITY ENTERPRISE 

In 2019, the Department of Homeland Security (DHS) Science 

and Technology Directorate (S&T) initiated a new lab-tomarket initiative, called the Commercialization Accelerator 

Program (CAP) that is focused on the transfer and 

commercialization of federally funded technology relevant to 

the Homeland Security Enterprise (HSE). CAP identifies, 

federally funded technologies for advancement into the 

commercial market where they are available to all homeland 

security end users. 

TAKING SOLUTIONS TO THE MARKETPLACE

CAP accomplishes its mission by: 

 Bridging the technology “valley of death” by providing

resources for manufacturing, production, demonstrations,

and providing support for scaling HSE-relevant federally

funded solutions.

 Building partnerships with private sector technology

developers, manufacturing and supply chain partners and

technology investor communities that can facilitate and

accelerate the commercialization process.

 Identifying potential technology transfer paths and

developing go-to-market strategies, including alternative

applications and markets.

APPROACH

CAP supports federally funded projects that demonstrate 

potential for commercialization with the following approach: 

 Identifying innovative technologies from Department of

Energy (DOE) National Laboratories, Department of

Defense (DoD) Laboratories, Federally Funded Research

and Development Centers (FFRDC), and University

Affiliated Research Centers (UARCs).

 Accelerating the path from lab to market by reducing the

risk in technologies to increase market readiness.

 Connecting researchers with strategic partners including

HSE operators, investors, and technology adopters.

PROCESS 

The CAP process advances the path from lab to market for 

selected technologies and includes market validation, 

commercialization training, testing and evaluation, pilot 

deployment, and partnership outreach. CAP technologies are 

introduced to potential partners and integrators and 

showcased at a variety of forums, conferences and events. 

CAP supports multiple paths to enable utilization by operators 

throughout the HSE, including licensing, start-up creation, 

open source and government use.

BENEFITS

 Enables a commercialization pathway for innovative

federally funded technologies that address a needed

capability that impacts the HSE end users.

 Increases utilization of federally funded research and

development (R&D) to deliver enhanced HSE capabilities

through partnerships, product development efforts and

commercialization.

 Improves the ability of federal government research

organizations to more efficiently advance HSE-relevant

technologies to the commercial marketplace.

CAP moves R&D from DOE National Laboratories, DOD Laboratories, FFRDCs, and UARCs

to the marketplace to enhance the capabilities of the Homeland Security Enterprise.

Contact Us: SandT.Innovation@hq.dhs.gov scitech.dhs.gov dhsscitech 

020 -2 10
---

---

Exhibit 13

Certification Pursuant to Rule
13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934.

In
connection with the Annual Report on Form 20-F of Ellomay Capital Ltd. (the
Company) for the year ended December 31, 2007 as filed with the Securities and
Exchange Commission on the date hereof (the Report), the undersigned officer
of the Company hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to
§906 of the Sarbanes-Oxley Act of 2002, that:

|A) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the
          Securities Exchange Act of 1934; and
|-- | -------------------------------------------------------------------------------------------------------------------------------

|B) | The information contained in the Report fairly presents, in all material
          respects, the financial condition and results of operations of the Company.
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | By: /s/ Yosef Zylberberg
Yosef ZylberbergInterim Chief   Executive   Officer   and  Chief Financial Officer
| |  | -------------------------------------------------------------------------------------------------------------------------

Date: June 30, 2008



---

---
38629.

#### DRAKE v. McGLASHAN *et al.*

Carlisle, Judge.

Questions of negligence and diligence including ordinary negligence and ordinary diligence and gross negligence and slight diligence *(Rowe v. Camp,*45 Ga, App. 794 (1), 165 S. E. 894; *Frye v. Pyron,*51 Ga. App. 613 (1), 181 S. E. 142), and of cause and proximate cause and whose negligence constituted the proximate cause of the plaintiff’s injuries are, except in plain, palpable and indisputable cases, solely for the jury, and the courts will decline to decide such questions on demurrer unless reasonable minds cannot differ as to the conclusion to be reached. *Long Construction Co. v. Ryals,*102 Ga. App. 66 (1) (115 S. E. 2d 726). “The simplest test of the sufficiency of a petition against general demurrer is whether the defendant can admit all that is alleged and still escape liability. *Georgia R. & Bkg. Co. v. Rayford,*115 Ga. *97937 (42 S. E. 234); *Pullman Palace Car Co. v. Martin,*92 Ga. 161 (18 S. E. 364).” *Harvey v. Zell,*87 Ga. App. 280, 284 (d) (73 S. E. 2d 605). The petition in this case being a suit against two defendants alleged to have been joint tortfeasors, alleges that the plaintiff’s husband was killed as the result of the concurring negligence of the two defendants; that the defendant Drake was the host driver of the automobile in which the plaintiff’s husband was riding; that he was negligent in driving his automobile at 90 miles per hour in the night time; in operating it across the white center line and on the left-hand side of the road; in failing to keep a lookout for approaching cars; and that such negligence was gross negligence which proximately caused him to collide with the truck of the defendant trucking company, the driver of which was also negligent in specified particulars, which collision inflicted injuries resulting in the death of the plaintiff’s husband. Under the rules of law set out above, the petition stated a cause of action against the defendant Drake and the trial court did not err in overruling his general demurrer.

Decided January 31, 1961.

*Sharpe & Sharpe, Bouhan, Lawrence, Williams, Levy & McAlpin,*for plaintiff in error.

*R. L. Dawson, Joseph T. Grice, Memory, Barnes & Memory,*contra.

*Judgment affirmed.*

*Townsend, P. J., Frankum and Jordan, JJ., concur.*
Electronically Filed Intermediate Court of Appeals CAAP-14-0000894 11-AUG-2015 09:32 AM
### Environmental consequences of the Retsof Salt Mine roof collapse

By: Richard M. Yager**

                            https://doi.org/10.3133/ofr20131174

#### Links

- More information:  **USGS Index Page**
-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report** 
- Companion File:  **Companion Files**
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
```

                                                                      EXHIBIT 32

                                ORTHOMETRIX, INC.
                          FORM 10-KSB DECEMBER 31, 2004

                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Annual Report of Orthometrix, Inc., (the "Company"),
on Form 10-KSB for the year ended December 31, 2004, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned, in the capacities and on the date indicated below, hereby certifies
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to his knowledge: (1) the Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities and Exchange
Act of 1934; and (2) the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the
Company.

Date: March 24, 2005                     /s/ Reynald Bonmati
                                         ---------------------------------------
                                         Reynald Bonmati
                                         Chief Executive Officer

Date: March 24, 2005                     /s/ Neil H. Koenig
                                         ---------------------------------------
                                         Neil H. Koenig
                                         Chief Financial Officer
```
Exhibit
32.1








CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002











In
connection with the Annual Report of Astea International Inc. (the “Company”) on
Form 10-K for the period ending December 31, 2007 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Zack Bergreen,
Chief Executive Officer and Principal Executive Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley
Act of 2002, that:





(1)
            The
      Report fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.














/s/Zack BergreenZack
      BergreenChief
      Executive Officer(Principal
      Executive Officer)April
      15, 2008
GENERAL TIPS

•	

•	

•	

•	

•	

•	

•	

Read the label. Follow all directions.

Wash your hands before you use the product.

Do not share makeup.

Keep the containers clean and closed tight when not in use.

Throw away cosmetics if the color or smell changes.

Do not use spray cans while you are smoking or near an open flame. 

It could start a fire.

Use aerosols or sprays in a place with good air flow.

EYE MAKE-UP TIPS

•	

•	

•	

•	

Do not add saliva or water to mascara. You could add germs.

Throw away your eye makeup if you get an eye infection. 

Do not use cosmetics near your eyes unless they are meant for your 

eyes. For example, do not use lip liner on your eyes.

Do not dye or tint your eyelashes. FDA has not approved any color 

additives for permanent dyeing or tinting of your eyelashes or 

eyebrows.

Lipstick

Nail Polish 

Deodorant

Perfume

Eye Make-Up

Hairspray

Face Cream

Bath Products
COSMETICS

BAD REACTION TO COSMETICS? 

FDA does not test cosmetics before they are sold 

in stores. However, FDA does monitor the safety 

of cosmetic products. Tell FDA if you have a rash, 

redness, burns, or other serious problems after using 

cosmetics. 

What Should You Do?

•	

•	

•	

Stop using the product.

Call your healthcare provider to find out how to 

take care of the problem.

Report serious problems to FDA at: 

www.fda.gov/medwatch/report.htm

or 1-800-332-1088

UNDERSTANDING COSMETIC LABELS

Read the label including the list of ingredients, warnings, and tips on how to use it safely.

•	Hypoallergenic: Do not assume •	 •	

that the product will not cause 

allergic reactions. FDA does not 

define what it means to be labeled 

‘hypoallergenic’. 

Organic or Natural: The source of 

the ingredients does not determine 

how safe it is. Do not assume 

that these products are safer than 

products made with ingredients 

from other sources. FDA does not 

define what it means to be labeled 

‘organic’ or ‘natural’.

Expiration Dates: Cosmetics are not 

required to have an expiration date. 

A cosmetic product may go bad if 

you store it the wrong way like if it 

is unsealed or in a place that is too 

warm or too moist.

Get other women’s health information: 

www.fda.gov/womens

Learn more about cosmetics: 

www.fda.gov/cosmetics

TAKE TIME TO CARE... For yourself, for those who need you.
<PAGE>

                                                                  EXHIBIT 23.1

             CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the incorporation by reference in the Registration Statement (Form
S-8 No. 333-00436) pertaining to the 1995 Director's Stock Option Plan, the
1995 Employee Stock Purchase Plan, the 1995 Stock Option Plan and the 1987
Stock Option Plan of our report dated February 6, 1997, with respect to the
consolidated financial statements of KeraVision, Inc. included in its Annual
report (Form 10-K) for the year ended December 31, 1996.

                                        ERNST & YOUNG LLP

San Jose, California
March 28, 1997
**Exhibit99.3**

 
|  | •      **Ernst  & Young****LLP**220 South Sixth Street, Ste  1400  Minneapolis, MN 55402-4509 | •      Phone: (612) 343-1000  www.ey.com |
|--|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|

 

Reportof Independent Registered Public Accounting Firm

 

Target National BankIts Officers and DirectorsAs Servicer

 

We have examined management’s assertion in theaccompanying report, Report of Management on Compliance, dated March 15, 2007,that Target National Bank (the Bank), as Servicer, complied in all materialrespects with the administration and servicing requirements of Article III,Article IV, and Section 8.8 of the Amended and Restated Pooling and ServicingAgreement, dated April 28, 2000, and the applicable provisions of the Series2002-1 Supplement, dated July 2, 2002, and the Series 2005-1  Supplement, dated November 9, 2005, to theTarget Credit Card Master Trust, as set forth in Exhibit A to the accompanyingReport of Management on Compliance as of December 30, 2006, and for the fiscalyear then ended. The Bank’s management is responsible for the Bank’s compliancewith those requirements. Our responsibility is to express an opinion onmanagement’s assertion based on our examination.

 

Our examination was conducted in accordance withattestation standards established by the Public Company Accounting OversightBoard (United States) and, accordingly,  includedexamining, on a test basis, evidence about the Bank’s compliance with those requirementsand performing such other procedures as we considered necessary in the circumstances.We believe that our examination provides a reasonable basis for our opinion.Our examination does not provide a legal determination on the Bank’s compliancewith specified requirements.

 

In our opinion, management’s assertion that the Bankcomplied with the aforementioned requirements as of and for the year endedDecember 30, 2006, is fairly stated, in all material respects.

 

 

March 15, 2007

 

A Member Practice ofErnst & Young Global

 

----
§ 20.40 Filing a request for records. ( a ) All requests for Food and Drug Administration records shall be made in writing by mailing or delivering the request to the Freedom of Information Staff at the address on the Agency's website at *https://www.fda.gov ,* by faxing it to the fax number listed on the Agency's website at *https://www.fda.gov ,* or by submission through the Agency's online FOIA submission portal at *https://www.fda.gov .* All requests must contain the postal address and telephone number of the requester and the name of the person responsible for payment of any fees that may be charged.
( b ) A request for Food and Drug Administration records shall reasonably describe the records being sought, in a way that they can be identified and located. A request should include all pertinent details that will help identify the records sought. ( 1 ) If the description is insufficient to locate the records requested, the Food and Drug Administration will so notify the person making the request and indicate the additional information needed to identify the records requested.
( 2 ) Every reasonable effort shall be made by the Food and Drug Administration to assist in the identification and location of the records sought.
( c ) Upon receipt of a request for records, the Division of Freedom of Information shall enter it in a public log. The log shall state the date received, the name of the person making the request, the nature of the record requested, the action taken on the request, the date of determination letter sent pursuant to § 20.41(b), and the date(s) any records are subsequently furnished.
( d ) A request by an individual, as defined in § 21.3(a) of this chapter, for a record about himself shall be subject to: ( 1 ) The special requirements of part 21 of this chapter (the privacy regulations), and not to the provisions of this subpart, if the record requested is retrieved by the individual's name or other personal identifier and is contained in a Privacy Act Record System, as defined in § 21.3(c) of this chapter.
( 2 ) The provisions of this subpart if the record requested is not retrieved by the individual's name or other personal identifier, whether or not the record is contained in a Privacy Act Record System.
[42 FR 15616, Mar. 22, 1977, as amended at 46 FR 8456, Jan. 27, 1981; 68 FR 25285, May 12, 2003; 76 FR 31469, June 1, 2011; 79 FR 68114, Nov. 14, 2014; 87 FR 55912, Sept. 13, 2022]
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     (Replace this text with the legend)
</LEGEND>
<CIK>                        0000813807                       
<NAME>                       COURTYARD BY MARRIOTT LIMITED PARTNERSHIP 
<MULTIPLIER>                                   1000
<CURRENCY>                                     U.S. DOLLAR
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-01-1999
<PERIOD-END>                                   MAR-26-1999
<EXCHANGE-RATE>                                1.00
<CASH>                                         14,904
<SECURITIES>                                   0
<RECEIVABLES>                                  5,636
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               18,689
<PP&E>                                         544,612
<DEPRECIATION>                                 (250,816)
<TOTAL-ASSETS>                                 333,025
<CURRENT-LIABILITIES>                          27,504
<BONDS>                                        325,461
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     (19,940)
<TOTAL-LIABILITY-AND-EQUITY>                   333,025 
<SALES>                                        0
<TOTAL-REVENUES>                               48,230
<CGS>                                          0
<TOTAL-COSTS>                                  0
<OTHER-EXPENSES>                               37,336
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             6,029
<INCOME-PRETAX>                                4,865
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            0
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   4,865
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
        


</TABLE>
```

[Federal Register Volume 78, Number 57 (Monday, March 25, 2013)]
[Notices]
[Pages 17992-17993]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-06755]

-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 8251]

Preparations for the International Telecommunication Union World 
Telecommunication Development Conference (ITU WTDC 2014)

SUMMARY: This notice announces meetings of the Department of State's 
International Telecommunication Advisory Committee (ITAC) to review the 
activities of its ad hoc group for preparations for the ITU World 
Telecommunication Development Conference (WTDC 2014), as well as 
preparations for other, related meetings at the ITU.
    The ITAC will meet on April 17, 2013 at 2PM EDT to review the work 
already performed in the ITAC-D ad hoc and the plans for preparation 
for related ITU meetings for the rest of this year. This meeting of the 
ITAC will be held at the Department of State, followed by additional 
meetings of the ITAC-D ad hoc of the ITAC on April 30, 2013 at 1300 Eye 
Street NW., Washington, DC fourth floor West Tower. Subsequent meetings 
of the ITAC-D and other ad hocs will be scheduled later.
    Details on these ITAC-D ad hoc meetings for preparations for WTDC14 
will be announced on the Department of State's email list, ITAC-D@lmlist.state.gov. Meetings of other ad hocs will be initially 
announced on the list: ITAC@lmlist.state.gov. Use of these lists is 
limited to meeting announcements and confirmations, distribution of 
agendas and other meeting documents such as Contributions.
    People desiring further information on these preparatory meetings, 
including those wishing to request reasonable accommodation to attend 
the meeting and those who wish to participate in the ITAC or ITAC-D 
lists, should contact the Secretariat at both minardje@state.gov and 
jminard@artelinc.com.
    Attendance at these meetings is open to the public as seating 
capacity allows.

[[Page 17993]]

The public will have an opportunity to provide comments at these 
meetings. A conference bridge will be provided to those people outside 
the Washington Metro area who request it from the secretariat.

    Dated: March 15, 2013.
Doreen McGirr,
Foreign Affairs Officer, International Communications & Information 
Policy, U.S. Department of State .
[FR Doc. 2013-06755 Filed 3-22-13; 8:45 am]
BILLING CODE 4710-07-P
```